UM PHARMA LIMITEDActive

Company number 10083250Private limited companyIncorporated 2016

Key figures

£142-97.1%
Net assets 2024/25
-31.8%
Average annual change 2019/20–2024/25
02 k4 k6 k2019/202020/212021/222022/232023/242024/25

Like most small UK companies, UM PHARMA LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2024/25
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
05 k10 k15 k2019/202020/212021/222022/232023/242024/25
Filed accounts2019/20–2024/25
2020/212021/222022/232023/242024/25
Cash at bank and in hand1,522———11,401
Total assets6,8835,9979,6244,122—
Total liabilities6,4737,1289,5218,98711,259
Net assets / total equity4101,1311034,865142
Average number of employees11111

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Principal activity

Accounts 2025

The company's principal activity during the year continued to be locum services.

As described in the company's latest filed accounts.

Summary: UM PHARMA LIMITED

Company

UM PHARMA LIMITED is a private limited company registered with Companies House under company number 10083250. It was incorporated on 24 Mar 2016. Its status is active. The registered office is in Birmingham (B11). Its nature of business (SIC 2007) is other human health activities (86900).

Accounts

The latest accounts in the database are for 2024/25 (period ending 31 Mar 2025); the company files small company accounts (filleted). Net assets were £142, down 97.1% on the previous year. Cash at bank and in hand was £11,401. The company had an average of 1 employee. Figures are available for 6 financial years (2019/20–2024/25).

Control and charges

One person with significant control is registered.

Filing deadlines

The next accounts are due by 31 Dec 2026. The next confirmation statement is due by 6 Apr 2027.